NCT03154385View on ClinicalTrials.gov

Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Rituximab (Mabthera ®) Belimumab (Benlysta ®)

Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12

Trial Locations (1)

94010

Henri Mondor Hospital, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03154385 - Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter